Nottingham, United Kingdom

Thomas Kerr Miller

This inventor holds 1 USPTO granted patent. Top assignee: Knoll Aktiengesellschaft. Active years: 1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thomas Kerr Miller. Retrieved from https://idiyas.com/inventor/thomas-kerr-miller

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 1998

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Thomas Kerr Miller: Innovator in Antirheumatic Research

Introduction

Thomas Kerr Miller is a notable inventor based in Nottingham, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with therapeutic potential.

Latest Patents

Miller holds a patent for "Condensed 4-aminopyridines with antirheumatic activity." This innovation showcases his commitment to advancing medical treatments for conditions such as arthritis.

Career Highlights

Miller is associated with Knoll Aktiengesellschaft, a company known for its focus on pharmaceutical research and development. His work there has been instrumental in exploring new therapeutic avenues.

Collaborations

Throughout his career, Miller has collaborated with esteemed colleagues, including Bernard John Armitage and Bruce William Leslie. These partnerships have fostered a collaborative environment that enhances innovation.

Conclusion

Thomas Kerr Miller's contributions to the field of antirheumatic research exemplify the impact of dedicated inventors in advancing medical science. His work continues to inspire future innovations in pharmaceuticals.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…